44.50MMarket Cap-381P/E (TTM)
1.7000High1.6203Low137.23KVolume1.6300Open1.6200Pre Close228.31KTurnover0.97%Turnover RatioLossP/E (Static)26.81MShares8.170052wk High-7.00P/B23.48MFloat Cap1.480052wk Low--Dividend TTM14.14MShs Float243.7500Historical High--Div YieldTTM4.92%Amplitude1.4800Historical Low1.6630Avg Price1Lot Size
Syros Pharmaceuticals Stock Forum
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
Bronstein, Gewirtz & Grossman, is investigating potential claims against Syros Pharmaceuticals, Inc. (NASDAQ:SYRS). The investigation follows Syros' announcement on August 12, 2024, that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial for a triplet regimen in acute myeloid leukemi...
Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial
Syros Pharmaceuticals (NASDAQ:SYRS) announced the discontinuation of enrollment in its SELECT-AML-1 Phase 2 clinical trial for acute myeloid leukemia (AML) treatment. The trial compared a triplet regimen (tamibarotene, venetoclax, and azacitidine) to a doublet regimen (venetoclax and azacitidine) in newly diagnosed, unfit AML patients with RARA gene overexpression.
The decision was based on a prespe...
Might be seeing an NDA as soon as next year if things keep looking up from the phase 3 results!
Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update :: Syros Pharmaceuticals, Inc. (SYRS)
No comment yet